The objective of the study was to assess the diagnostic process, access to care and treatment adequacy for primary adrenal insufficiency (PAI) patients from a US-based online registry.
The National Adrenal Diseases Foundation (NADF) patient registry from 2015 to 2016 was used for a cross-sectional assessment of PAI patients. Five hundred and forty-one adults met the study inclusion criteria (US residents, age >20, self-reported physician diagnosis of PAI and replacement dosing for cortisol). Issues in diagnosis, comorbid conditions, symptoms, with demographic and socioeconomic characteristics were determined. Disease management assessment included medication dose, patient satisfaction with function, and education. Factors associated with adrenal crisis were noted.
The cohort was predominantly female (83%), non-Hispanic White (97%), and well-educated (94% > high school education). A majority (57%) of patients reported difficulty with initial diagnosis, while 27% felt that their current steroid replacement was not adequate. Comorbid thyroid disease and other autoimmune conditions were common among PAI patients in the registry. More than three-quarters (78%) of patients used hydrocortisone for glucocorticoid replacement with a mean dose of 24.4 (standard deviation [SD]: 8.7) mg. Mean dose of hydrocortisone has declined over time following current treatment recommendations.
Timely, accurate diagnosis remains a problem for patients with primary adrenal insufficiency in an affluent, well-educated US cohort. Episodes of adrenal crisis are common and replacement steroid treatment is not always effective for patient function. Comprehensive information about outcomes of care for PAI in the US remains limited and the establishment of a research-specific registry to foster future research may be desirable. Patient registry data is a valuable source of information on diagnostic error and outcomes of care in rare diseases.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
Disclosure: The authors report no conflicts of interest in this work.
1. Bergthorsdottir R, Leonsson-Zachrisson M, Oden A, Johannsson G. Premature mortality in patients with Addison’s disease: a population-based study. J Clin Endocrinol Metab 2006;91:4849–53. Search in Google Scholar
2. Bensing S, Hulting AL, Husebye ES, Kampe O, Lovas K. Management of endocrine disease: epidemiology, quality of life and complications of primary adrenal insufficiency: a review. Eur J Endocrinol 2016;175:R107–16. Search in Google Scholar
3. Hahner S, Spinnler C, Fassnacht M, Burger-Stritt S, Lang K, Milovanovic D, et al. High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. J Clin Endocrinol Metab 2015;100:407–16. Search in Google Scholar
4. Puar TH, Stikkelbroeck NM, Smans LC, Zelissen PM, Hermus AR. Adrenal crisis: still a deadly event in the 21st century. Am J Med 2016;129:339 e331–9. Search in Google Scholar
5. Erichsen MM, Løvås K, Skinningsrud B, Wolff AB, Undlien DE, Svartberg J, et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab 2009;94:4882–90. Search in Google Scholar
6. Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun 2009;33:197–207. Search in Google Scholar
7. Meyer G, Badenhoop K, Linder R. Addison’s disease with polyglandular autoimmunity carries a more than 2.5-fold risk for adrenal crises: German health insurance data 2010–2013. Clin Endocrinol (Oxf) 2016;85:347–53. Search in Google Scholar
8. Bleicken B, Hahner S, Ventz M, Quinkler M. Delayed diagnosis of adrenal insufficiency is common: a cross-sectional study in 216 patients. Am J Med Sci 2010;339:525–31. Search in Google Scholar
9. Papierska L, Rabijewski M. Delay in diagnosis of adrenal insufficiency is a frequent cause of adrenal crisis. Int J Endocrinol 2013;2013:482370. Search in Google Scholar
10. Quinkler M, Hahner S, Johannsson G, Stewart PM. Saving lives of patients with adrenal insufficiency: a pan-European initiative? Clin Endocrinol (Oxf) 2014;80:319–21. Search in Google Scholar
11. Johannsson G, Falorni A, Skrtic S, Lennernäs H, Quinkler M, Monson JP, et al. Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy. Clin Endocrinol (Oxf) 2015;82:2–11. Search in Google Scholar
12. Bleicken B, Hahner S, Loeffler M, Ventz M, Decker O, Allolio B, et al. Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2010;72:297–304. Search in Google Scholar
13. Husebye ES, Allolio B, Arlt W, Badenhoop K, Bensing S, Betterle C, et al. Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med 2014;275:104–15. Search in Google Scholar
14. Bornstein SR, Allolio B, Arlt W, Barthel A, Don-WauchopeA, Hammer GD, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2016;101: 364–89. Search in Google Scholar
15. Kaufmann P, Pariser AR, Austin C. From scientific discovery to treatments for rare diseases – the view from the National Center for Advancing Translational Sciences – Office of Rare Diseases Research. Orphanet J Rare Dis 2018;13:196. Search in Google Scholar
16. Ambrosini A, Calabrese D, Avato FM, Catania F, Cavaletti G, Pera MC, et al. The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage. Orphanet J Rare Dis 2018;13:176. Search in Google Scholar
17. Culver DA, Behr J, Belperio JA, Corte TJ, de Andrade JA, Flaherty KR, et al. Patient registries in idiopathic pulmonary fibrosis (IPF). Am J Respir Crit Care Med 2019. doi: 10.1164/rccm.201902-0431CI. [Epub ahead of print]. Search in Google Scholar
18. Jackson AD, Goss CH. Epidemiology of CF: how registries can be used to advance our understanding of the CF population. J Cyst Fibros 2018;17:297–305. Search in Google Scholar
19. Strange C. Rare disease registries: steps forward. Chronic Obstr Pulm Dis 2019;6:126–8. Search in Google Scholar
20. Elborn JS, Gonska T. Using registries for research in CF. How can we be sure about the outputs? J Cyst Fibros 2019;18:309–310. Search in Google Scholar
21. Greenhalgh J, Dalkin S, Gooding K, Gibbons E, Wright J, Meads D, et al. In Functionality and feedback: a realist synthesis of the collation, interpretation and utilisation of patient-reported outcome measures data to improve patient care. NIHR Journals Library National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK, Southampton (UK), 2017. Search in Google Scholar
22. Schiff GD, Hasan O, Kim S, Abrams R, Cosby K, Lambert BL, et al. Diagnostic error in medicine: analysis of 583 physician-reported errors. Arch Intern Med 2009;169:1881–7. Search in Google Scholar
23. Whittaker MJ, Debono M, Huatan H, Merke DP, Arlt W, Ross RJ. An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisone exposure. Clin Endocrinol (Oxf) 2014;80:554–61. Search in Google Scholar
24. Rushworth RL, Torpy DJ. Adrenal insufficiency in Australia: is it possible that the use of lower dose, short-acting glucocorticoids has increased the risk of adrenal crises? Horm Metab Res 2015;47:427–32. Search in Google Scholar
©2019 Walter de Gruyter GmbH, Berlin/Boston